We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
181 own
50 watching
Current Price
$285.51
$-0.43
(-0.15%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
152,319.58M
52-Week High
296.67
52-Week Low
200.835
Average Volume
2.27M
Dividend Yield
0.032184
P/E Ratio
21.7238
Market Capitalization152,319.58M
52-Week High296.67
52-Week Low200.835
Average Volume2.27M
Dividend Yield0.032184
P/E Ratio21.7238
What does the Stockal+Disclaimer.pdf do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
4days ago
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 PR Newswire THOUSAND OAKS, Calif., Dec. 1, 2022 AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results...
Zolmax
18days ago
Amgen (NASDAQ:AMGN Get Rating) had its price objective boosted by investment analysts at Oppenheimer to $300.00 in a research note issued on Tuesday, Stock Target Advisor reports. Oppenheimers target price would indicate a potential upside of 5.72% from the companys previous close. AMGN has been the...
PR Newswire
1month ago
Thinking about trading options or stock in Alphabet, Microsoft, Tesla, Visa, or Amgen? Thinking about trading options or stock in Alphabet, Microsoft, Tesla, Visa, or Amgen? PR Newswire NEW YORK, Oct. 26, 2022 NEW YORK, Oct. 26, 2022 /PRNewswire/ -- InvestorsObserverissues critical PriceWatch...
PR Newswire
1month ago
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire THOUSAND OAKS, Calif., Oct. 20, 2022 TAVNEOS(avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$285.51
$-0.43
(-0.15%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00